AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25875447 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g dried ginger root powder (morning and afternoon intake)
Number of subjects: 0
Study 23596262 — intervention group
Group type: COMPARATOR
Intervention: Single dose of praziquantel (40 mg/kg body weight)
Number of subjects: 395
Study 23596262 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of praziquantel (first dose followed by a second dose 2 weeks later)
Number of subjects: 395
Study 20360498 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine
Number of subjects: 72
Study 20360498 — intervention group
Group type: COMPARATOR
Intervention: Water‐soluble lubricating gel alone (control)
Number of subjects: 72
Study 18392897 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery (RYGBP)
Number of subjects: 7
Study 16357081 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n = 10)
Number of subjects: 16
Study 16357081 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 6)
Number of subjects: 16
Study 12791192 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostant
Number of subjects: 119
Study 10793541 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% carteolol hydrochloride (30 microliters, twice daily for 7 days)
Number of subjects: 10
Study 10793541 — intervention group
Group type: COMPARATOR
Intervention: Placebo (30 microliters)
Number of subjects: 10
Study 8712390 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-Hz tetanic stimuli
Number of subjects: 22
Study 8712390 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-Hz tetanic stimuli
Number of subjects: 22
Study 8712390 — intervention group
Group type: COMPARATOR
Intervention: neostigmine (40 micrograms/kg)
Number of subjects: 22
Study 1857658 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis with anesthetic
Number of subjects: 10
Study 1857658 — intervention group
Group type: COMPARATOR
Intervention: Iontophoresis with placebo
Number of subjects: 10
Study 6354728 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 6
Study 6354728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30091121 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief personalized informational video (3-5 min)
Number of subjects: 459
Study 30091121 — intervention group
Group type: COMPARATOR
Intervention: Standard care (legislatively required letter about MBD)
Number of subjects: 459
Study 30400832 — intervention group
Group type: EXPERIMENTAL
Intervention: LiFE (individually delivered lifestyle-integrated functional exercise program)
Number of subjects: 300
Study 30400832 — intervention group
Group type: COMPARATOR
Intervention: gLiFE (group-delivered lifestyle-integrated functional exercise program)
Number of subjects: 300
Study 30400832 — intervention group
Group type: EXPERIMENTAL
Intervention: LiFE
Number of subjects: 300
Study 30400832 — intervention group
Group type: COMPARATOR
Intervention: gLiFE
Number of subjects: 300
Study 30400832 — intervention group
Group type: EXPERIMENTAL
Intervention: LiFE and gLiFE
Number of subjects: 300
Study 27008904 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable light (concentration and soothing programs)
Number of subjects: 30
Study 27008904 — intervention group
Group type: COMPARATOR
Intervention: Standard lighting
Number of subjects: 30
Study 23780902 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) during recovery periods of Repeated Sprint Ability (RSA) tests
Number of subjects: 17
Study 21293243 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 6) plus Paclitaxel (200 mg/m²) on day 1 (CP)
Number of subjects: 89
Study 21293243 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (1000 mg/m²) plus Vinorelbine (25 mg/m²) on days 1 and 8 (GV)
Number of subjects: 89
Study 21293243 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin plus Paclitaxel (CP)
Number of subjects: 89
Study 21293243 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus Vinorelbine (GV)
Number of subjects: 89
Study 19719526 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgotul™
Number of subjects: 25
Study 19719526 — intervention group
Group type: COMPARATOR
Intervention: Tulle-gras (TG)
Number of subjects: 25
Study 17945036 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m(2) over 100 minutes on days 1 and 15 in combination with oxaliplatin 100 mg/m(2) over 2 hours on days 2 and 16, every 4 weeks.
Number of subjects: 10
Study 15094442 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I ablation after lobectomy
Number of subjects: 225
Study 15094442 — intervention group
Group type: COMPARATOR
Intervention: 131I ablation after total thyroidectomy
Number of subjects: 225
Study 15094442 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-ablative 131I neck uptake
Number of subjects: 225
Study 15094442 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body 131I burden 2 days post-therapy
Number of subjects: 225
Study 15094442 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological half-life of radioiodine
Number of subjects: 225
Study 15094442 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum thyroglobulin levels at 3 months post-ablation
Number of subjects: 225
Study 11761092 — intervention group
Group type: EXPERIMENTAL
Intervention: Separate management of suction blood using the Avant D903 oxygenator (n = 11)
Number of subjects: 21
Study 11761092 — intervention group
Group type: COMPARATOR
Intervention: Control group with suction blood filtered and redirected immediately (n = 10)
Number of subjects: 21
Study 9737282 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented enteral nutrition
Number of subjects: 72
Study 9737282 — intervention group
Group type: COMPARATOR
Intervention: Control group (balanced, isonitrogenous, isocaloric enteral feeding)
Number of subjects: 72
Study 7827294 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (n = 10)
Number of subjects: 17
Study 7827294 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (n = 7)
Number of subjects: 17
Study 7827294 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 17
Study 3050570 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches
Number of subjects: 131
Study 3050570 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 131
Study 3050570 — intervention group
Group type: COMPARATOR
Intervention: Behavioral training alone
Number of subjects: 131
Study 8466265 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEpo) 50 to 150 U administered subcutaneously twice a week from 7 days of age until discharge
Number of subjects: 24
Study 8466265 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEpo)
Number of subjects: 24
Study 8466265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 104378 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium aurothiomalate
Number of subjects: 26
Study 104378 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillamine
Number of subjects: 26
Study 31595391 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive analgesia of celecoxib
Number of subjects: 100
Study 31595391 — intervention group
Group type: COMPARATOR
Intervention: Postoperative analgesia of celecoxib
Number of subjects: 100
Study 31215467 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (NaF) dentifrice
Number of subjects: 0
Study 31215467 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride (AmF) dentifrice
Number of subjects: 0
Study 31215467 — intervention group
Group type: COMPARATOR
Intervention: Fluoridated bioactive glass dentifrice
Number of subjects: 0
Study 27418422 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional virtual reality vestibular rehabilitation (modified Cawthorne-Cooksey exercises: eye, head, extension, and coordination exercises) performed in six training sessions over 4 weeks.
Number of subjects: 70
Study 27418422 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 70
Study 26435200 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjoint analysis intervention
Number of subjects: 0
Study 26435200 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 23398142 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention group based on the 7 Steps of the Baby Friendly Community Initiative (BFCI)
Number of subjects: 1781
Study 23398142 — intervention group
Group type: COMPARATOR
Intervention: Late intervention group based on the 7 Steps of the Baby Friendly Community Initiative (BFCI)
Number of subjects: 1781
Study 21557378 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Adherence Questionnaire (MAQ)
Number of subjects: 119
Study 21557378 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance Rating Scale (CRS)
Number of subjects: 119
Study 21557378 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug Attitude Inventory (DAI)
Number of subjects: 119
Study 19464612 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% N(2)O in O(2) for three minutes
Number of subjects: 73
Study 19464612 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% N(2)O in O(2) for 5 minutes
Number of subjects: 73
Study 19464612 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% N(2)O in O(2) for three minutes
Number of subjects: 73
Study 19464612 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% N(2)O in O(2) for 5 minutes
Number of subjects: 73
Study 19464612 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 73
Study 17712244 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (10 mg/day for the first week and 20 mg/day thereafter)
Number of subjects: 96
Study 17712244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 17712244 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine and Placebo (CDRS‐R and MADRS)
Number of subjects: 96
Study 17712244 — intervention group
Group type: EXPERIMENTAL
Intervention: CDRS‐R
Number of subjects: 96
Study 17712244 — intervention group
Group type: EXPERIMENTAL
Intervention: MADRS
Number of subjects: 96
Study 17712244 — intervention group
Group type: EXPERIMENTAL
Intervention: CDRS‐R and MADRS
Number of subjects: 96
Study 14733787 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-amniotic administration of pulmonary surfactant (PS)
Number of subjects: 45
Study 14733787 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 45
Study 11395840 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced warm air blanket
Number of subjects: 100
Study 11395840 — intervention group
Group type: COMPARATOR
Intervention: Cotton blanket
Number of subjects: 100
Study 9951629 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 0
Study 9951629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7810285 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT therapy
Number of subjects: 10
Study 7810285 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving AZT)
Number of subjects: 10
Study 2843722 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone (200 mg t.i.d.)
Number of subjects: 73
Study 2843722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 31308062 — intervention group
Group type: EXPERIMENTAL
Intervention: Monalizumab 10 mg/kg i.v. every 2 weeks
Number of subjects: 58
Study 27866841 — intervention group
Group type: EXPERIMENTAL
Intervention: Thai Yoga (TY)
Number of subjects: 39
Study 27866841 — intervention group
Group type: COMPARATOR
Intervention: Tai Chi (TC)
Number of subjects: 39
Study 26129831 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindlight (experimental condition)
Number of subjects: 120
Study 26129831 — intervention group
Group type: COMPARATOR
Intervention: Triple Town (control condition)
Number of subjects: 120
Study 24238518 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075% ropivacaine
Number of subjects: 200
Study 24238518 — intervention group
Group type: COMPARATOR
Intervention: 0.1% ropivacaine
Number of subjects: 200
Study 21632509 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin with PF-3512676 (0.2 mg/kg subcutaneous on days 8 and 15)
Number of subjects: 828
Study 21632509 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel/carboplatin alone (control arm)
Number of subjects: 828
Study 21632509 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin with PF-3512676
Number of subjects: 828
Study 19646346 — intervention group
Group type: EXPERIMENTAL
Intervention: ANCA against PR3
Number of subjects: 44
Study 19646346 — intervention group
Group type: COMPARATOR
Intervention: ANCA against deglycosylated recombinant variants of PR3
Number of subjects: 44
Study 16393305 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v (10^11 CFU/day) for 2 weeks
Number of subjects: 29
Study 16393305 — intervention group
Group type: COMPARATOR
Intervention: Placebo (without L. plantarum 299v)
Number of subjects: 29
Study 15341559 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (500 mg/d) and vitamin D (400-600 IU/d) supplements
Number of subjects: 2565
Study 11146898 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-a-day administration of interferon-alpha
Number of subjects: 47
Study 11146898 — intervention group
Group type: COMPARATOR
Intervention: Once-a-day administration of interferon-alpha
Number of subjects: 47
Study 8856002 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine, 20 mg daily
Number of subjects: 671
Study 8856002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 671
Study 8856002 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 671
Study 8856002 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine and Placebo
Number of subjects: 671
Study 1627944 — intervention group
Group type: EXPERIMENTAL
Intervention: wuzi yanzong solution (WYS)
Number of subjects: 80
Study 1627944 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study 6697796 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-breathing exercises
Number of subjects: 12
Study 6697796 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-breathing exercises with vibrations
Number of subjects: 12
Study 6697796 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 12
Study 29370992 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab monotherapy (3 mg/kg every 2 weeks)
Number of subjects: 85
Study 29370992 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses, then nivolumab monotherapy)
Number of subjects: 85
Study 29370992 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab monotherapy
Number of subjects: 85
Study 29370992 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 85
Study 29272007 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with ice stimulation
Number of subjects: 40
Study 29272007 — intervention group
Group type: COMPARATOR
Intervention: Routine examinations, graded swallowing training, radio frequency electrotherapy, acupuncture, dietary guidance, body position and compensation training
Number of subjects: 40
Study 26282726 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg (D110)
Number of subjects: 14283
Study 26282726 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg (D150)
Number of subjects: 14283
Study 26282726 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (W)
Number of subjects: 14283
Study 26282726 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients
Number of subjects: 14283
Study 23971173 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary nodule management based on volumetry
Number of subjects: 0
Study 20139920 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine (0.4 mg)
Number of subjects: 15
Study 20139920 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg)
Number of subjects: 15
Study 18264747 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-inhibitors, angiotensin receptor blockers (ARBs), and aldosterone antagonists
Number of subjects: 0
Study 18264747 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 0
Study 18264747 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan and spironolactone
Number of subjects: 0
Study 16085437 — intervention group
Group type: EXPERIMENTAL
Intervention: IV paracetamol 2g
Number of subjects: 297
Study 16085437 — intervention group
Group type: COMPARATOR
Intervention: IV paracetamol 1g
Number of subjects: 297
Study 16085437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study 12823597 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a (40 kDa) 90 microg
Number of subjects: 194
Study 12823597 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a (40 kDa) 180 microg
Number of subjects: 194
Study 12823597 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a (40 kDa) 270 microg
Number of subjects: 194
Study 12823597 — intervention group
Group type: COMPARATOR
Intervention: conventional interferon alpha‐2a 4.5 MIU
Number of subjects: 194
Study 12823597 — intervention group
Group type: EXPERIMENTAL
Intervention: All peginterferon alpha‐2a (40 kDa) doses combined
Number of subjects: 194
Study 10082229 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-methyl-para-tyrosine (AMPT)
Number of subjects: 10
Study 10082229 — intervention group
Group type: COMPARATOR
Intervention: promethazine (placebo)
Number of subjects: 10
Study 7569092 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric screen-film systems (InSight HC and High Light GCA)
Number of subjects: 200
Study 7569092 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical homogenized (Tau-Gil Homogenized)
Number of subjects: 200
Study 7569092 — intervention group
Group type: COMPARATOR
Intervention: Conventional high-kilovoltage techniques
Number of subjects: 200
Study 7569092 — intervention group
Group type: EXPERIMENTAL
Intervention: High Light GCA system
Number of subjects: 200
Study 7569092 — intervention group
Group type: EXPERIMENTAL
Intervention: InSight system
Number of subjects: 200
Study 2327646 — intervention group
Group type: EXPERIMENTAL
Intervention: Respirgard II (smallest droplet size profile)
Number of subjects: 9
Study 2327646 — intervention group
Group type: COMPARATOR
Intervention: Acorn System 22 (largest droplet size profile)
Number of subjects: 9
Study 2327646 — intervention group
Group type: EXPERIMENTAL
Intervention: Respirgard II with inspiratory baffle removed
Number of subjects: 9
Study 6797778 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-selective beta-blockade (pindolol, 15 mg daily)
Number of subjects: 0
Study 6797778 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardio-selective blockade (metoprolol, 200 mg)
Number of subjects: 0
Study 6797778 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardio-selective blockade (acebutolol, 500 mg)
Number of subjects: 0
Study 6797778 — intervention group
Group type: COMPARATOR
Intervention: Control (4 weeks treatment)
Number of subjects: 0
Study 31823135 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMT (Laser 100 mW, 808 nm, 159.24 J/cm2/point, 5 J/point)
Number of subjects: 15
Study 31823135 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMT + exoskeleton
Number of subjects: 15
Study 31823135 — intervention group
Group type: COMPARATOR
Intervention: Placebo + PBMT
Number of subjects: 15
Study 31815658 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrates (PCC)
Number of subjects: 50
Study 31815658 — intervention group
Group type: COMPARATOR
Intervention: Fresh frozen plasma (FFP)
Number of subjects: 50
Study 31815658 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment
Number of subjects: 50
Study 27504889 — intervention group
Group type: EXPERIMENTAL
Intervention: SAGAT tool for assessing situational awareness (SA)
Number of subjects: 43
Study 26522063 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocker
Number of subjects: 62
Study 26522063 — intervention group
Group type: COMPARATOR
Intervention: X-Stop
Number of subjects: 62
Study 26522063 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study 23715889 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid filler (Glytone 1, HA concentration: 14 mg/g)
Number of subjects: 55
Study 23715889 — intervention group
Group type: COMPARATOR
Intervention: Saline physiological solution (control)
Number of subjects: 55
Study 21482607 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly healthy lifestyle group (intervention)
Number of subjects: 106
Study 21482607 — intervention group
Group type: COMPARATOR
Intervention: Monthly school-readiness group (control)
Number of subjects: 106
Study 19652934 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B lozengers
Number of subjects: 40
Study 19652934 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 17292880 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 39
Study 17292880 — intervention group
Group type: EXPERIMENTAL
Intervention: Perhexiline
Number of subjects: 39
Study 17292880 — intervention group
Group type: EXPERIMENTAL
Intervention: Perhexiline pre-treatment with Nitroglycerin
Number of subjects: 39
Study 15335126 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer Screening Office Systems (Cancer SOS) intervention
Number of subjects: 1196
Study 11431176 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg/d)
Number of subjects: 0
Study 11431176 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/d)
Number of subjects: 0
Study 11431176 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of Enalapril and Losartan
Number of subjects: 0
Study 11431176 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of Enalapril and Losartan (doubled doses)
Number of subjects: 0
Study 9478178 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncology home care (OHC)
Number of subjects: 46
Study 9478178 — intervention group
Group type: COMPARATOR
Intervention: Standard home care
Number of subjects: 46
Study 9478178 — intervention group
Group type: COMPARATOR
Intervention: Office care control
Number of subjects: 46